Daeyu Co., Ltd. Overview
Daeyu is a 49-year-old Korean specialty agri-inputs manufacturer. Its franchise was built on foliar-applied (leaf-spray) specialty fertilizers. Its flagship, Nargen (나르겐), launched in 1978, is described by the company as Korea's first foliar-application Class-4 compound fertilizer. The company has since broadened into certified organic agricultural materials, a modest crop-protection (pesticide) line, plant-growth regulators and quasi-drugs for livestock use. It sells mainly through Korea's dense network of independent agro-chemical and seed retailers (about 72% of Q1 FY2025 sales) and through NongHyup (about 27%). Annual revenue is roughly KRW 34bn, and it has stayed between KRW 30bn and 36bn every year from FY2020 to FY2025. Operating margins have typically been high single digits to high teens. Between 2020 and 2025, however, its corporate story was dominated by ownership and governance events rather than operations. A leveraged change of control in 2020 was followed by a circular cross-shareholding with Jogwang ILI and Andiforce, the 2023 indictment of then-CEO Kim Woo-dong, three consecutive years of net losses, and delisting in 2025. Since delisting, Daeyu has operated as a privately traded, Jogwang ILI-controlled company. Competitors Chobi and Kyungnong hold a contested 18% minority block.
Company's own description. In its filings, Daeyu describes itself as a company founded in Gyeongsan in April 1977 whose main business is manufacturing and selling fertilizers and pesticides, together with manufacturing, importing and selling quasi-drugs (shareholder meeting notice, KIND, Nov 2024). The same document says Daeyu maintains a high share in Class-4 foliar compound fertilizers, built on infrastructure developed over 48 years. It says the company is using its sales network to expand newer lines such as pesticides. Management attributes recent revenue softness to temporary competitive intensity and a slowing market. It expects growth to resume as pesticide consumption declines structurally and demand for eco-friendly organic materials rises, and it describes itself as the number-one eco-friendly specialty-fertilizer supplier. The Q1 FY2025 quarterly report (KIND, 15 May 2025) repeats this outlook and attributes the 2025 dip to an economic slump and regional disasters such as wildfires.
The NICE registry lists Daeyu's business purposes as manufacturing Class-4 compound fertilizer and pesticides, wholesale and retail, e-commerce, quasi-drug manufacturing, and leasing of non-residential buildings (Saramin/Jobkorea). Its manufacturing licences cover Class-4, Class-3 and Class-1 compound fertilizers, micronutrient fertilizers, lime and magnesia fertilizers, organic fertilizers, eco-friendly organic materials, other fertilizers and crop protection agents (company profile via Saramin).
Business model. Daeyu is predominantly a branded product manufacturer. It earns revenue from the sale of manufactured goods (제품) and traded or imported goods (상품). Imported products have included Dutch-origin specialty fertilizers such as the Fertigro line (Etoday, Aug 2021). There is no material subscription, service or licensing revenue. The building-leasing purpose suggests minor rental income from its Seoul headquarters building, but the amount is not disclosed.
Value-chain position. Daeyu sits at the formulation and branding stage. It buys raw nutrients, active ingredients, natural extracts and microbial strains, then formulates them into liquid, powder, granular and, since 2021, high-concentration gel-fluid products. It sells to distributors that serve farmers. It does not produce commodity nitrogen, phosphate or potash; those are dominated in Korea by Namhae Chemical and similar producers. Its value lies in formulation know-how, product registrations (fertilizer, organic-material and pesticide registrations), test-laboratory designations, and farmer-facing brand recognition.
Customer types and channels. The Q1 FY2025 quarterly report (KIND) shows three domestic channels:
The end-customers are Korean farmers, concentrated in horticulture (fruit trees, vegetables, protected cultivation), rice and specialty crops. Smaller segments include home gardening (the "MyFarming" kit launched May 2022), tree and landscape care (a stated development priority in 2021), livestock (quasi-drugs and livestock-housing materials listed on the company website) and, from 2019, aerial and wide-area application through 14 products designed for drone or aircraft spraying (company history).
End-markets. These are Korean specialty and foliar fertilizers, certified organic agricultural materials (유기농업자재), crop protection (notably plant growth regulators such as gibberellin and insecticides such as abamectin products), and a small, early-stage export business (Thailand, Japan, Mongolia, Kazakhstan, Egypt).
Independent characterization. Daeyu is a niche, cash-generative specialty formulator with a strong rural brand and a retailer-heavy distribution model. Its scale is small (about KRW 34bn revenue) and its growth has been flat for six years. The operating business appears to have been reasonably resilient through the governance crisis: operating income was positive in four of the last five years and recovered to KRW 2.8bn in FY2025. The equity story, however, was impaired by non-core investments made at the parent's direction, most prominently the Andiforce stake, and by the governance failures that led to delisting. The key analytical tension is a sound, if small, operating franchise held inside a contested and opaque ownership structure.
Strategy
Stated strategic themes (management statements in filings and releases).
-
Eco-friendly shift. Management expects structural decline in pesticide consumption and growth in certified organic materials. It positions Daeyu as the leading eco-friendly specialty-fertilizer player and stresses differentiated eco-friendly fertilizers and pesticides (KIND shareholder notice, Nov 2024; Q1 FY2025 report).
-
Pesticide line extension through the existing retailer network (KIND, Nov 2024).
-
Export diversification into Thailand, Japan, Mongolia, Kazakhstan and Egypt, alongside domestic government-subsidy programmes (Edaily, Aug 2024; company history).
-
Manufacturing modernization. The automated Goesan Smart Campus is meant to lower costs and improve efficiency (Edaily, Aug 2024).
-
New product development. Priorities include high-concentration gel fluids, pesticide range expansion, tree-care products and organic materials (Etoday, Aug 2021), and more recently neem-based pest management (Nongmin, Jan 2025).
-
Digital marketing through YouTube (Daeyu-man channel) and online retail (Etoday, Aug 2021; company history).
Initiatives in the last 24 months (Oct 2024 – Oct 2026).
Medium-term financial targets and guidance. None are publicly disclosed. The only stated orientation is a qualitative expectation that revenue will return to growth. In 2018, the then-CEO described the specialty-fertilizer niche as part of a domestic fertilizer market of about KRW 3tn (Etoday, Jul 2018).
Cost programmes. The "diet management" declaration (January 2021) is the only named cost programme. SG&A and one-off costs fell 11.0% in H1 FY2024 (Edaily, Aug 2024). No quantified targets are disclosed.
ESG commitments. No public emissions or sustainability targets.
Products & Services
Portfolio breadth. At its 2018 IPO, Daeyu reported about 1,500 fertilizer products, 43 pesticide products and 56 organic agricultural material products (Etoday, Jul 2018). In 2021 it cited about 1,200 items (Etoday, Aug 2021). In 2020 it cited about 70 specialty-fertilizer products and claimed the number-one share in foliar fertilizers, including Class-4 compound fertilizers (Wonyesanup, Sep 2020). The website organizes products into five categories: Fertilizers, Organic Agricultural Materials, Crop Protection, Quasi-drugs, and Livestock-housing Materials. Pricing is not publicly disclosed for any product.
Fertilizers (foliar and specialty compound fertilizers)
| Product / line | Description and capability | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Nargen (나르겐) and derivatives (Super Nargen, New Nargen, Double Nargen) | Foliar Class-4 compound fertilizer; credited with reviving a protected pine in 1980 | Horticulture and fruit growers; tree care | 1978 (original) | Flagship; +16.3% in H1 2021 |
| Mirigeun (미리근) / Mirigeun Alpha | Root-promotion fertilizer line | Vegetable and fruit growers | — | Named core line (NICE 2026) |
| Burio (부리오) / Burio Gold | Specialty compound fertilizer line | Horticulture | — | Named core line (NICE 2026) |
| Calcium and micronutrient range (e.g., Daeyu Calcium 100, Fast Calcium 23, Boron, Selenium, Germanium products) | Correction of deficiencies and physiological disorders | Fruit and vegetable growers | Various | Listed in website product keywords |
| Fruit-sizing and colouring fertilizers | Fruit enlargement, colour promotion, ripening | Orchards | Patents from 2005–2006 | Patents on colour-promotion and selenium compound fertilizers |
| High-Enriched Gel Fluid formulation | New high-concentration gel-fluid fertilizer format | Growers seeking efficient application | Jan 2021 | Gel products exported to Thailand from Aug 2024 |
| Aerial and wide-area application range (14 products) | Fertilizers and organic materials formulated for aerial or drone spraying | Rice and field-crop growers; co-ops | Jun 2019 | Company called it a domestic first |
| MyFarming (마이파밍) | Home-gardening plant-nutrient set | Consumers | May 2022 | B2C extension |
| Imported specialty fertilizers (e.g., Fertigro (퍼트그로)) | Dutch-origin specialty fertilizers | Growers | — | +81.2% in H1 2021 |
Organic Agricultural Materials (certified eco-friendly inputs)
| Product / line | Description | Launch / latest | Notes |
|---|---|---|---|
| Daeyu Nargen Organic | Natural-extract organic agricultural material | Mar 2017 | Certified eco-friendly material |
| Chongjinssak (총진싹) series | Organic pest-management material | — | +664.8% in H1 2021 |
| Mulpure (물푸레) series | Organic material series | — | +271.0% in H1 2021 |
| Neem-extract pest-management product | Pest management based on neem (subtropical plant) extract | 2025 (announced) | Nongmin, Jan 2025 |
| Super Kelp (슈퍼켈프) | Seaweed-based organic material | Exported to Egypt Jan 2026 | Company history |
| Richen Fulvic (리첸풀빅) | Fulvic-acid organic material | Exported to Kazakhstan Feb 2026 | Company history |
| Chitosan liquid (대유키토산액제) | Eco-friendly chitosan product | 2,002 | Full production supplied to NongHyup in 2002 |
| Hoechunto (회춘토) granules | Eco-friendly soil material | Aug 2003 | Company history |
| Garujaba (가루자바) | Product to reduce powdery mildew and grey mould damage | Dec 2003 | Company history |
| Plant-oil formulations (One-Stop, One-Shot 51) | Eco-friendly plant-oil formulations | Jan 2003 | Company history |
| Soil conditioners | Exported to Japan | 2024–2025 | Company history |
The company claimed the largest number of organic-material registrations in Korea (Nongupin, 2018).
Crop Protection (pesticides and plant growth regulators)
| Product | Description | Notes |
|---|---|---|
| Gibberellin (지베레린) products, including a paste formulation with visual application marking | Plant growth regulator | Patent filing on a marked gibberellin paste (application no. 10-2017-0027264) |
| Abamec-kill (아바멕킬) | Abamectin-based insecticide/acaricide | Named core crop-protection line (NICE 2026) |
| Ethephon liquid (에렐폰액제) | Growth regulator | Produced from Mar 2003 |
| Zinc-lime Bordeaux wettable powder | Fungicide | Patent registered Jan 2008 |
| Microbial pesticides (e.g., 불로토, 회춘토 water-soluble formulations; Dr. Plant (닥터푸란트), Soil 0119, Chanchanchan liquid formulations) | Microbial control agents | Produced from 2000 |
| Pollination aid / fruit-thinning sprays | Patented compositions (pollen-removal spray, Sep 2018) | Company history |
Quasi-drugs and Livestock-housing Materials
Daeyu registered quasi-drug manufacturing in December 2011. Its website lists quasi-drug and livestock-housing material categories, and filings refer to "animal quasi-drugs." Individual products, specifications and revenue are not publicly disclosed. Quarantine and disinfection products were described as under development in 2018 (Nongupin).
Digital and Direct Channels
The company runs a Naver SmartStore online shop, a Naver blog, and the YouTube channel "Daeyu-man" (대유맨), which passed 100,000 subscribers in November 2025 (company history). Management stated in 2021 that it would use YouTube to drive sales (Etoday, Aug 2021).
Financial Narrative
Income Statement
FY2022 net income is KRW -17.6bn per FnGuide and KRW -17.94bn per NICE; the discrepancy is noted. FY2025 pre-tax income was KRW 0.64bn, and a tax benefit of KRW 0.35bn lifted net income to KRW 0.98bn (NICE via Jobkorea).
Margins and Growth (%)
Revenue CAGR. FY2021–FY2025: about -1.9% per year (36.3 to 33.7). FY2020–FY2025: about 0.0% (33.6 to 33.7). In effect, revenue has gone nowhere for six years.
Balance Sheet: notes and sources
Source: FnGuide (FY2022–FY2024) and NICE via Jobkorea (FY2025). FY2025 borrowings are derived from NICE's borrowings-to-assets ratio of 15.41% applied to total assets; this is an approximation. Cash and equivalents, the short/long-term debt split, goodwill and intangibles are not publicly disclosed. Total assets were KRW 94.37bn in 2020 (Wikipedia KO). Property, plant and equipment (land and buildings) had a book value of KRW 36.3bn at 30 June 2025 (Hankyung Market Insight, Aug 2025).
Cash Flow
FY2025 operating cash flow was KRW 6.33bn. Investing cash flow was a net inflow of KRW 4.72bn, the source of which is not disclosed. NICE also reports "cash operating income" of KRW 7.01bn (all NICE via Jobkorea). Capital-raising and outflow events: the KRW 34bn rights offering (Feb 2022) and the early redemption of the KRW 7.0bn second-series CB (Jun 2023).
Ratios
ROE and ROA for FY2023–FY2024 are computed on average balances. FnGuide reports FY2024 ROE of -10.12%, consistent with the computed figure. FY2025 ratios are from NICE via Jobkorea or computed from its figures. ROIC (1.04%, NICE) is not tabulated separately. Net debt/EBITDA cannot be computed because EBITDA and cash are not disclosed. A partial cash-conversion estimate gives about 27 days of receivables and about 121 days of inventory; payables days are not disclosed, so the full cash conversion cycle cannot be computed.
Interim Data Points
Q1 FY2025 revenue is shown as KRW 10.1bn by FnGuide and as KRW 10.6bn by the sum of the KIND channel table; the discrepancy is noted. Q1 FY2025 gross profit was KRW 5.01bn versus KRW 5.13bn a year earlier, and OP was KRW 1.45bn versus KRW 2.03bn (KIND).
Commentary on Trends, Inflections and Drivers
Revenue: a flat franchise with sharp seasonality. Revenue has stayed in a KRW 30–36bn band since FY2020. The FY2023 dip (-13.8%) coincided with the trading suspension, the indictment and an emergency management structure. Management attributed it to temporary competitive intensity and a weak market. FY2024 recovered 11.1%, led by fertilizer and organic materials (+10.6% for 9M) and pesticides and animal quasi-drugs (+10.8%). FY2025 was flat (-0.8%), and the company cited economic weakness and regional disasters such as wildfires. Seasonality is extreme. Q4 FY2024 revenue was only KRW 1.8bn against KRW 9.6bn in Q3, which is consistent with the filing's statement that pesticide sales run from pre-season preparation (February) through harvest (September).
Operating profitability: from high-teens margin to high single digits. The FY2021 margin of 17.6% followed the 2021 "diet management" cost programme and record H1 sales. The H1 FY2021 margin of 35.5% was offset by an H2 operating loss of about KRW 2.2bn, implying heavy Q4 cost absorption. Margins compressed in FY2022 (12.7%), turned negative in FY2023 (-1.8%) and recovered to 6.6% in FY2024 and 8.4% in FY2025. Management credits the recovery to SG&A cuts (one-off and SG&A expenses down 11.0% in H1 FY2024) and efficiency gains at the Goesan plant, which entered full operation in early 2024 (Edaily, Aug 2024). The FY2025 gross margin of about 49% indicates strong pricing power at the formulation level. Operating expenses of about KRW 13.6bn (gross profit less OP) absorb most of it. For a KRW 34bn business, that SG&A load is heavy and reflects the field-sales-driven retailer model.
The below-the-line problem. The defining feature of FY2022–FY2024 is the gap between operating results (positive in FY2022 and FY2024) and net results (cumulative net losses of about KRW 47.7bn over three years). The sources do not itemize these losses. The pattern is consistent with valuation losses and impairments on non-operating investments, of which the Andiforce stake is the most significant known exposure. Prosecutors alleged that Daeyu paid about KRW 6.5bn for a partnership interest holding Andiforce shares that later fell to about KRW 4.4bn (Hankyung, Jan 2026). Andiforce itself recorded large valuation losses on its biotech investments (Dealsite, Apr 2025). This attribution is an analytical inference, not a disclosed breakdown.
Balance sheet: deleveraged and equity-heavy, but shrunk. Total assets fell from KRW 142.4bn (FY2022) to KRW 95.2bn (FY2025), and equity fell from KRW 106.5bn to KRW 77.0bn. Liabilities halved from KRW 35.8bn to KRW 18.1bn, helped by the June 2023 early redemption of the KRW 7.0bn CB. The equity ratio of 81% and current ratio of 2.08x indicate low financial risk. The FY2022 balance sheet had been inflated by the February 2022 KRW 34bn rights offering. Part of that cash went into the Goesan plant (about KRW 19bn earmarked); the rest is not traceable in the sources reviewed.
Returns. On FY2025 average equity of about KRW 76.5bn, ROE was 1.3%. An operating business producing KRW 2.8bn of OP on KRW 77bn of book equity earns a low return on capital. This reflects a capital base swollen by the 2022 raise, idle or non-core assets (Andiforce stake, Seoul real estate), and the new plant's still-modest throughput.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Fertilizer & agro-materials segment revenue (KRW Bn) | 36.3 | 35.4 | 30.5 | 33.9 | 33.7 |
Segment operating income (KRW Bn) | 6.4 | 4.5 | -0.5 | 2.2 | 2.8 |
Segment operating margin (%) | 17.6 | 12.7 | -1.8 | 6.6 | 8.4 |
Segment revenue YoY growth (%) | 8.0 | -2.5 | -13.8 | 11.1 | -0.8 |
Share of total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Product Category Details
| Product category | Disclosed mix / growth | Period | Source |
|---|---|---|---|
Fertilizers & organic materials (Nargen, Mirigeun, Burio series) | 85–87% of revenue | 2026 interim periods | NICE via Jobkorea |
Crop protection (gibberellin, Abamec-kill) | 12–14% of revenue | 2026 interim periods | NICE via Jobkorea |
Fertilizers & organic materials | +9.0% YoY | H1 FY2024 | Edaily, Aug 2024 |
Pesticides | +11.2% YoY | H1 FY2024 | Edaily, Aug 2024 |
Animal quasi-drugs | +4.4% YoY | H1 FY2024 | Edaily, Aug 2024 |
Fertilizers & organic materials | +10.6% YoY | 9M FY2024 | Company release (Financial News), Nov 2024 |
Pesticides & animal quasi-drugs | +10.8% YoY | 9M FY2024 | Company release, Nov 2024 |
Nargen series | +16.3% YoY | H1 FY2021 | Etoday, Aug 2021 |
Mirigeun series | +14.2% YoY | H1 FY2021 | Etoday, Aug 2021 |
Burio series | +5.5% YoY | H1 FY2021 | Etoday, Aug 2021 |
Dutch-origin imports (Fertigro etc.) | +81.2% YoY | H1 FY2021 | Etoday, Aug 2021 |
Chongjinssak (총진싹) organic pest-management series | +664.8% YoY | H1 FY2021 | Etoday, Aug 2021 |
Mulpure (물푸레) organic series | +271.0% YoY | H1 FY2021 | Etoday, Aug 2021 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 36.3 | 35.4 | 30.5 | 33.9 | 33.7 |
Gross profit (KRW Bn) | — | — | — | — | 16.4 |
Operating income (KRW Bn) | 6.4 | 4.5 | -0.5 | 2.2 | 2.8 |
Pre-tax income (KRW Bn) | — | — | — | — | 0.6 |
Net income (KRW Bn) | — | -17.6 | -22.0 | -8.1 | 1.0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | — | — | — | — | 48.7 |
Operating margin (%) | 17.6 | 12.7 | -1.8 | 6.6 | 8.4 |
Net margin (%) | — | -49.7 | -72.1 | -23.9 | 2.9 |
Revenue growth YoY (%) | 8.0 | -2.5 | -13.8 | 11.1 | -0.8 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 142.4 | 106.8 | 94.1 | 95.2 |
Current assets (KRW Bn) | — | — | — | 35.7 |
Non-current assets (KRW Bn) | — | — | — | 59.5 |
Total liabilities (KRW Bn) | 35.8 | 22.5 | 18.1 | 18.1 |
Current liabilities (KRW Bn) | — | — | — | 17.1 |
Total equity (KRW Bn) | 106.5 | 84.3 | 76.0 | 77.0 |
Paid-in capital (KRW Bn) | 12.4 | 12.4 | 12.4 | 12.4 |
Working capital (KRW Bn) | — | — | — | 18.5 |
Total debt / borrowings (KRW Bn, derived) | — | — | — | 14.7 |
Cash Flow
| Metric | FY2025 |
|---|---|
Operating cash flow (KRW Bn) | 6.3 |
Investing cash flow (KRW Bn) | 4.7 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | — | -23.1 | -10.1 | 1.3 |
ROA (%) | — | -17.7 | -8.1 | 1.0 |
Liabilities to equity (%) | 33.6 | 26.7 | 23.8 | 23.5 |
Equity ratio (%) | 74.8 | 78.9 | 80.8 | 81.0 |
Current ratio (x) | — | — | — | 2.08 |
Quick ratio (%) | — | — | — | 145.1 |
Interest coverage (x) | — | — | — | 4.77 |
Asset turnover (x) | — | — | — | 0.36 |
Receivables turnover (x) | — | — | — | 13.45 |
Inventory turnover (x) | — | — | — | 3.01 |
Revenue History
| Period | Revenue (KRW Bn) | Operating income (KRW Bn) | Net income (KRW Bn) | Source |
|---|---|---|---|---|
H1 FY2021 | 24.2 | 8.6 | — | Etoday, Aug 2021 |
H1 FY2024 | 22.5 | 5.4 | 1.5 | Edaily, Aug 2024 |
9M FY2023 | 29.0 | 4.3 | — | Nongmin, Jan 2025 |
9M FY2024 | 32.1 | 6.8 | 5.0 | Company release, Nov 2024 |
Q3 FY2024 | 9.6 | 1.3 | — | FnGuide |
Q4 FY2024 | 1.8 | -4.5 | — | FnGuide (derived from FY less 9M) |
Q1 FY2025 | 10.1–10.6 | 1.45 | — | FnGuide; KIND Q1 report |
H1 FY2025 | 21.8 | 4.7 | — | Nongmin, Sep 2025 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 30.5 | 33.9 | 33.7 |
Market by Date
| Date | Market | Products |
|---|---|---|
Mar 2000 | First exports (destination not disclosed) | — |
Jun 2023 | Thailand | Nargen, amino-acid products |
Mar 2024 | Japan | Organic materials, soil conditioners |
Jun 2024 | Mongolia | Organic materials |
Aug 2024 | Thailand (expansion) | Gel-formulation products, organic materials |
Jan 2025 | Japan (expansion) | Soil conditioners |
May 2025 | Kazakhstan | Test-bed support programme participation |
Jan 2026 | Egypt | Super Kelp |
Feb 2026 | Kazakhstan | Richen Fulvic |
“—” = not publicly disclosed.
Share Price
| Metric | FY2018 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|
Reference share price (KRW) | 8,900 | 5,460 | 2,300 | 500 |
Analyst Conclusions
Management guidance. No quantitative guidance. Qualitatively, management expects a return to revenue growth driven by eco-friendly organic materials, pesticide line extension, domestic subsidy programmes and exports (KIND Q1 FY2025; Edaily, Aug 2024).
Consensus. None (no coverage).
Bull case
-
The operating franchise is intact and improving. OP recovered from KRW -0.5bn (FY2023) to KRW 2.8bn (FY2025), and net income turned positive (KRW 0.98bn) for the first time in at least four years. That occurred during suspension, delisting and litigation.
-
Deep asset backing. Book equity of KRW 77.0bn with an 81% equity ratio. Land and buildings had a book value of KRW 36.3bn (Jun 2025). There is an Andiforce stake of about 18% plus a modern plant. The last observed market transactions (about KRW 900 per share) imply roughly 0.3x book.
-
Strategic optionality. Two domestic sector players (Chobi and Kyungnong) have already paid to secure 18.24%, and Kyungnong previously bid for the parent. This creates a credible path to a consolidation exit that could crystallize synergies in distribution and R&D.
Bear case
-
Growth is absent. Revenue CAGR is about 0% over FY2020–FY2025, the core domestic farm market is structurally challenged, and exports remain immaterial in disclosed figures.
-
Governance discount may be permanent. KRX and a court found transparency deficits. The parent's ultimate ownership has been questioned, and minority holders lack an exchange exit. Value leakage through related-party transactions has precedent in the Andiforce purchase.
-
Capital is poorly employed. ROE of about 1.3% on a large equity base, with non-core assets that have historically generated losses. Without disposals or distributions, minority shareholders may not capture asset value.
Key catalysts and monitorables (next 12 months)
-
FY2026 results and the H1 FY2026 margin trajectory, including whether the FY2025 OP recovery holds.
-
Verdict in Kim Woo-dong's criminal trial and any civil recovery by Daeyu.
-
Appeal outcome in the delisting-nullity litigation (low probability of relisting).
-
Any disposal of the Andiforce stake or of Seoul real estate.
-
Moves by Chobi and Kyungnong: further accumulation, litigation, or a negotiated transaction with Jogwang ILI.
-
Changes in Jogwang ILI's ownership (the JS Innovation Partners–Alpenroute fund; Dong Jin International).
-
Export traction in Egypt and Kazakhstan, and whether any export revenue is disclosed.
-
Raw-material cost pass-through amid 2026 geopolitical volatility.
-
Dividend policy, given minority-holder pressure for distributions.
Concluding analyst verdict.
Daeyu is a case study in how a sound, modest operating business can be overwhelmed by its capital structure and governance. The core franchise is real. Nargen and its sister lines have been sold for nearly five decades, gross margins run near 49%, and the company kept generating operating profit and positive operating cash flow through two years of suspension and a contested delisting. FY2025's return to net profit, on flat revenue of KRW 33.7bn, suggests the drag from non-operating investments has largely run its course, and the balance sheet is now conservative.
The structural problem is not leverage but stewardship. From 2020 the company was embedded in a chain of cross-holdings through Jogwang ILI and Andiforce. Capital raised from the public in 2022 coincided with the period in which non-core exposures generated roughly KRW 48bn of cumulative net losses. Both the exchange and the court concluded that transparency had not been restored. Delisting has removed the main external discipline on management just as a competitor bloc and a minority alliance remain inside the shareholder base. For minority holders, the investment case now depends almost entirely on a corporate event, such as a sale to a strategic buyer, a disposal of non-core assets, or a meaningful distribution policy, rather than on operating growth, which has been absent for six years.
On a standalone basis, Daeyu should be viewed as a stable but low-growth, low-return specialty formulator worth well above its last traded price on an asset basis. That value is not readily accessible because the controlling shareholder's interests may not align with those of minority holders. Positive monitorables are export disclosure, Andiforce monetization and dividends. Negative signals would be further related-party dealings or renewed leadership churn. The overall assessment is a sound operating asset inside an impaired governance structure, best approached as special-situations exposure rather than an operating-growth thesis.
APPENDIX A — DATA GAPS (NOT PUBLICLY DISCLOSED IN SOURCES REVIEWED)
-
Auditor; executive compensation; board committee structure; chair identity.
-
R&D expense; total patent count.
-
EBITDA; depreciation; capex; cash balance; debt maturity profile; EPS and DPS history.
-
Revenue by geography and export revenue.
-
Segment-level revenue in KRW by product category.
-
Final IPO price.
-
Current status of the Gyeongsan and Jincheon sites.
-
Appeal status in the delisting suit.
-
Verdict in the former CEO's criminal trial.
-
Scope of the 2025–2026 MOUs (Central Bio, T-Chem, The Gyun).
APPENDIX B — PRINCIPAL SOURCES
-
Daeyu company history page: http://dae-yu.com/html/company_history.html
-
Daeyu Q3 FY2024 release (company news page): https://www.dae-yu.co.kr/html/public_news_view.html?b_idx=NzM5MyAg
-
KIND Q1 FY2025 quarterly report excerpt: https://kind.krx.co.kr/external/2025/05/15/002489/20250515005821/11013.htm
-
KIND shareholders' meeting notice (Nov 2024): https://kind.krx.co.kr/external/2024/11/28/000799/20241128001613/00591.htm
-
FnGuide company page (A290380): https://comp.fnguide.com/SVO2/ASP/SVD_Main.asp?gicode=A290380
-
Jobkorea / NICE company profile (FY2025 financials, history, headcount): https://m.jobkorea.co.kr/company/44535016
-
Saramin / NICE company profile: https://www.saramin.co.kr/zf_user/company-info/view/csn/UngwSWQ0bmorV2VrL0twbGMvYTEzUT09/company_nm/(%EC%A3%BC)%EB%8C%80%EC%9C%A0
-
Korean Wikipedia, 대유: https://ko.wikipedia.org/wiki/%EB%8C%80%EC%9C%A0
-
Etoday, IPO briefing (Jul 2018): https://www.etoday.co.kr/news/view/1644861
-
Etoday, H1 2021 record results: https://www.etoday.co.kr/news/view/2053737
-
Eugene Investment IPO reports (Jul and Oct 2018): https://www.eugenefn.com/common/files/amail/20180710_B_jongsun.park_864.pdf ; https://www.eugenefn.com/common/files/amail/20181016_B_jongsun.park_915.pdf
-
Dealsite, change-of-control SPA (Jul 2020): https://dealsite.co.kr/articles/63141 ; https://dealsite.co.kr/articles/63211
-
Hankyung Market Insight, family dispute and sale (Jul 2020): https://marketinsight.hankyung.com/article/202007208529u
-
Newsfm, Jogwang ILI acquisition (Sep 2020): https://www.newsfm.kr/news/article.html?no=5066
-
Wonyesanup, new CEO (Sep 2020): http://www.wonyesanup.co.kr/news/articleView.html?idxno=47378
-
Financial News, Andiforce stake (Sep 2021): https://www.fnnews.com/news/202109171721117111
-
News Tomato, rights offering (Feb 2022): https://newstomato.com/ReadNews.aspx?no=1106072
-
Smart Today, arrest and limit-down (Apr 2023): https://www.smarttoday.co.kr/ko-kr/articles/28679
-
Seoul Economic TV, indictment (Apr 2023): https://www.sentv.co.kr/article/view/sentv202304270005
-
Dealsite, delisting review and CB default (Aug 2023): https://dealsite.co.kr/articles/107979
-
Newsfm, delisting decision (Sep 2023): https://www.newsfm.kr/news/article.html?no=8298
-
Edaily, H1 2024 results: https://edaily.co.kr/News/Read?mediaCodeNo=257&newsId=02158246638987976
-
iNews24 via Nate, delisting and board changes (Jan 2025): https://news.nate.com/view/20250122n17272
-
Nongmin Shinmun, delisting decision (Jan 2025): https://www.nongmin.com/article/20250124501088
-
Seoul Economic Daily, tender offer (Feb 2025): https://www.sedaily.com/article/14027540
-
Etoday, Jogwang ILI new controlling fund (Dec 2024): https://www.etoday.co.kr/news/view/2428004
-
The Bell / Money Today, governance restructuring (Apr 2025): https://www.mt.co.kr/stock/2025/04/22/2025042208059676093
-
Nongsaro / Nongmin, final delisting and H1 2025 results (Sep 2025): https://www.nongsaro.go.kr/portal/ps/psx/psxs/newsMainView.ps?newsSeqNo=127749&menuId=PS65437
-
Hankyung Market Insight, Chobi stake (Aug 2025): https://marketinsight.hankyung.com/article/202508213569r
-
DigitalToday, Chobi stake detail (Aug 2025): https://www.digitaltoday.co.kr/news/articleView.html?idxno=586591
-
Agrinet, EGM shareholding (Oct 2025): https://www.agrinet.co.kr/news/articleView.html?idxno=340885
-
Greened, control-contest analysis (Oct 2025): https://www.greened.kr/news/articleView.html?idxno=332067
-
Dealsite TV, EGM outcome (Oct 2025): https://news.dealsitetv.com/articles/160206
-
Newsfm, Chobi and Kyungnong criticism (Oct 2025): https://www.newsfm.kr/news/article.html?no=10349
-
Livesnews, company position on litigation (Oct 2025): https://livesnews.com/mobile/article.html?no=55876
-
Hankyung, delisting-nullity suit dismissed (Jan 2026): https://www.hankyung.com/article/202601274699i
-
Law Times, Kim Woo-dong trial (2025): https://www.lawtimes.co.kr/news/articleView.html?idxno=212630
-
Numbers, Kim Woo-dong trial witness (2026): https://www.numbers.co.kr/news/articleView.html?idxno=20328
-
Dealsite, Andiforce investment losses (Apr 2025): https://dealsite.co.kr/articles/139465
-
Butler.works peer financials (Chobi; Nuvo): https://www.butler.works/ko/companies/00148948 ; https://www.butler.works/ko/companies/01394669
-
Catch / Valueline, Kyungnong profile: https://www.catch.co.kr/Comp/RecruitInfo/350281 ; https://www.valueline.co.kr/finance/summary/002100
-
Asia Economy, Chobi market share and industry structure: https://view.asiae.co.kr/article/2022051614560111221
-
Nuvo technology analysis report (CRF market): https://file.alphasquare.co.kr/media/pdfs/company-ir/20250614%EB%88%84%EB%B3%B4_%EA%B8%B0%EC%97%85%EB%B6%84%EC%84%9D%EB%B3%B4%EA%B3%A0%EC%84%9C_%EB%B0%9C%EA%B0%84.pdf
-
finanztrends.de quote page (ISIN; Jan 2022 price): https://www.finanztrends.de/aktie/daeyu
-
Investing.com, liquidation-trading price: https://www.investing.com/equities/daeyu-co-ltd
-
Simply Wall St (listing inactive): https://simplywall.st/stocks/kr/materials/kosdaq-a290380/dae-yu-shares/health
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background | Source |
|---|---|---|---|---|
Nam Eul-jin (남을진) | CEO | Mar 2026 to present | Also CEO of parent Jogwang ILI (succeeded Hong Gi-heung there in 2025). Prior roles, education and age not disclosed. | NICE via Jobkorea and Saramin |
Jo Sin-hwan (조신환) | Inside director | Elected 15 Oct 2025 EGM | — | Dealsite TV, Oct 2025 |
Seo Jang-ho (서장호) | Outside director | Appointed Dec 2024 | Director, Cham Accounting Corporation | iNews24, Jan 2025 |
Lee Young-seok (이영석) | Outside director | Appointed Dec 2024 | Representative judicial scrivener, Minwoo office | iNews24, Jan 2025 |
Statutory auditor (name not disclosed) | Auditor | — | The company stated in Oct 2025 that an auditor was already in office | Dealsite TV, Oct 2025 |
“—” = not publicly disclosed.
Board & Management Changes
| Period | CEO(s) | Context |
|---|---|---|
Mar 2014 – Jun 2015 | Kwon Ok-sul | Founding-family era |
Jun 2015 – Sep 2020 | Kwon Sung-han | Led the 2018 IPO; sold control to Jogwang ILI in 2020 |
Sep 2020 – Mar 2023 | Kim Woo-dong | Cornell economics graduate; formerly at Merrill Lynch and Liberty PE (Wonyesanup, Sep 2020). Arrested Apr 2023. |
Mar 2023 – Sep 2023 | Kim Woo-dong and Kim Cheol-han (co-CEOs) | Crisis period |
Sep 2023 – Dec 2024 | Jeong Chi-hun | Improvement-period management |
Dec 2024 – Mar 2026 | Lee Beop-jong | Appointed with full board refresh before the final KRX review |
Mar 2026 to present | Nam Eul-jin | Concurrent with the Jogwang ILI CEO role |
Major Shareholders
| Holder | Stake | As of | Source |
|---|---|---|---|
Jogwang ILI Co., Ltd. | about 47.97% | Oct 2025 | Agrinet; Newsfm |
Chobi Co., Ltd. (KOSPI: 001550) | 9.67% | Aug 2025 | DigitalToday; Hankyung MI |
Kyungnong Corp. (KOSPI: 002100) | 8.02% | Aug 2025 | DigitalToday |
Chobi/Kyungnong related persons (Lee Seung-yeon, Lee Yong-jin, Lee Byung-man) | 0.55% | Aug 2025 | Agrinet |
Minority Shareholders' Alliance (via ACT platform) | 26.5% per Agrinet, or about 15% per the company's register count | Oct 2025 | Agrinet; Greened |
Other public holders | Remainder | Oct 2025 | Derived |
Competitive Landscape
Market Share by Competitor
| Competitor | Segment overlap | FY2025 revenue | Market share / position | Notes | Source |
|---|---|---|---|---|---|
Namhae Chemical (남해화학) | Fertilizers (commodity and compound) | — | Ranked 1st by NICE | Large-scale producer | Jobkorea ranking |
Pungnong (풍농) | Compound fertilizers | — | Ranked 2nd | — | Jobkorea ranking |
Chobi (조비, KOSPI 001550) | Compound and slow-release fertilizers | KRW 99.7bn (OP KRW 3.8bn) | About 9.4–9.7% of the national fertilizer market | Now an 18.24% Daeyu holder with Kyungnong | Butler.works; Valueline; Asia Economy |
Nuvo (누보, KOSDAQ 332290) | Controlled-release coated, effervescent and functional fertilizers; crop protection; golf-course turf | KRW 104.2bn (OP KRW 4.1bn) | Ranked 4th | Strong in coated CRF technology | Butler.works; Jobkorea |
Seoul Bio (서울바이오) | Microbial and organic materials | — | Ranked 5th | — | Jobkorea ranking |
Segi (세기) | Fertilizers | — | Ranked 6th | — | Jobkorea ranking |
Korea Agro (코리아아그로) | Fertilizers | — | Ranked 9th | — | Jobkorea ranking |
Dongsin (동신) | Fertilizers | — | Ranked 10th | — | Jobkorea ranking |
Jeju Fertilizer (제주비료) | Fertilizers | — | Ranked 11th | — | Jobkorea ranking |
Kyungnong (경농, KOSPI 002100) | Crop protection (more than 95% of standalone revenue); fertilizers via subsidiary Chobi | KRW 232.3bn (+8.5%) | Major domestic crop-protection player | Parent of Chobi | Catch.co.kr; Valueline |
Nongwoo Bio (농우바이오) | Seeds, plus growing media, fertilizers and pesticides | — | KOSDAQ-listed total agri-input player | — | Korea IR Council report |
Peer Comparison FY2025
| Metric | Daeyu | Chobi | Nuvo | Kyungnong |
|---|---|---|---|---|
Revenue (KRW Bn) | 33.7 | 99.7 | 104.2 | 232.3 |
Revenue growth (%) | -0.8 | -2.6 | 5.2 | 8.5 |
Operating income (KRW Bn) | 2.8 | 3.8 | 4.1 | — |
Operating margin (%) | 8.4 | 3.8 | 3.9 | — |



